The Microbiome–Gut–Brain Axis: Mechanisms, Dysbiosis, and Clinical Implications

Sheiza Asif

2nd Year MBBS, Islamabad Medical and Dental College, Islamabad, Pakistan

Key points:

- Introduction
- Development of Gut Microbiome
- The Gut-Brain axis
- The Microbiome-Gut-Brain Axis
- Clinical Significance
- Gut Brain axis and Alzheimer's Disease
- Future Perspectives
- Conclusion

Introduction

The statement "All disease begins in the gut," commonly attributed to Hippocrates, reflects an idea that has gained substantial scientific support over recent decades. Early Greek physicians—including Hippocrates, Plato, and Aristotle—recognized the interconnection between the brain and the gastrointestinal tract [1]. In the nineteenth century, William Beaumont demonstrated that emotional states could alter digestion, providing early scientific evidence of brain gut communication [1]. Since then, advances in neuroscience, microbiology, and molecular biology have established continuous bidirectional communication through the complex network known as the gut–brain axis. Recent discoveries reveal that the gut microbiome plays a central role in maintaining this communication. Alterations in microbial composition, termed gut dysbiosis, have been linked to numerous neurological, psychiatric, metabolic, and inflammatory disorders [2]. Although significant progress has been made, the precise mechanisms through which the microbiome influences brain function remain incompletely understood, making the microbiome–gut–brain axis a critical area of ongoing research.




Figure 1: *Branches of the vagus and other cranial nerves carrying sensory information from the alimentary canal to the brainstem, and dissemination of this information to the rest of the brain* [3].

Development of The Gut Microbe

The human gut microbiome is a highly diverse ecosystem of bacteria, viruses, fungi, and archaea that begins developing before birth and matures during the first few years of life [5]. During infancy, the microbiome undergoes rapid changes before stabilizing into an

adult-like composition by approximately three years of age a period coinciding with rapid brain growth, suggesting mutual influence between both systems [5]. A healthy microbiome is essential for immune maturation, intestinal barrier function, and normal neurodevelopment [5]. Factors such as maternal infections, poor nutrition, cesarean delivery, excessive antibiotic use, and environmental stressors can disrupt microbial balance. Early-life dysbiosis may trigger chronic inflammation and immune dysfunction, increasing susceptibility to neurodevelopmental and psychiatric disorders later in life [6].




Figure 2: *Summary of components of enteric nervous system and function. GIT: Gastrointestinal tract [7].*

The Gut–Brain Axis

The gut–brain axis is a bidirectional communication network linking the gastrointestinal tract with the central nervous system. Communication occurs through multiple interconnected pathways: the Vagus nerve, enteric nervous system (ENS), autonomic nervous system (ANS), hypothalamic–pituitary–adrenal (HPA) axis, endocrine signaling, and immune mediators [7]. Together these systems regulate gastrointestinal motility, secretion, nutrient absorption, immune responses, and emotional behavior. The enteric nervous system often called the body's "second brain" independently coordinates digestive functions while continuously exchanging signals with the brain [7]. The autonomic nervous system additionally regulates intestinal permeability, mucus production, blood flow, and immune activity, enabling the brain to rapidly modify gut physiology in response to stress or environmental change.

The Microbiome–Gut–Brain Axis

The gut microbiome regulates gut–brain communication by producing metabolites, neurotransmitters, and signaling molecules that influence both intestinal and brain function. Beneficial microbes synthesize short-chain fatty acids (SCFAs), serotonin, gamma-aminobutyric acid (GABA), dopamine precursors, and other neuroactive substances that directly or indirectly affect neuronal signaling [8]. Conversely, the brain influences the gut microbiome through HPA axis and autonomic nervous system activation. During stress, cortisol and norepinephrine alter gastrointestinal motility, permeability, mucus secretion, and microbial composition [9]. This bidirectional feedback loop means changes in either the brain or the gut propagates to the other.

Clinical Significance

Growing evidence links gut microbiome dysbiosis with numerous neurological and psychiatric disorders, including depression, anxiety, autism spectrum disorders (ASD), schizophrenia, Parkinson's disease, multiple sclerosis, and irritable bowel syndrome [2,10]. Alterations in microbial diversity promote systemic inflammation, disrupt neurotransmitter production, and impair intestinal barrier integrity, ultimately affecting brain function and behavior. These findings have stimulated interest in microbiome-based therapeutic strategies, including probiotics, prebiotics, dietary modification, fecal microbiota transplantation (FMT), and microbial metabolites as potential treatments for gut–brain axis disorders [11].

Gut–Brain Axis and Alzheimer's Disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β plaque deposition, tau protein accumulation, neuroinflammation, and cognitive decline [12]. Increasing

evidence suggests that gut microbiome dysbiosis contributes to AD through disruption of the microbiome–gut–brain axis. An imbalanced gut microbiota increases intestinal permeability, enabling bacterial endotoxins and inflammatory mediators to enter systemic circulation and influence the brain [13]. Chronic systemic inflammation activates microglial cells, enhances neuroinflammation, and accelerates amyloid-β deposition all contributing to neuronal degeneration. Conversely, a healthy microbiome produces beneficial SCFAs that maintain blood–brain barrier integrity, reduce inflammation, and support neuronal survival [14]. Dietary compounds such as phytosterols have been shown to modify gut microbiota composition, improve lipid metabolism, suppress neuroinflammation, and reduce amyloid pathology in experimental AD models [15]. Further clinical studies are required before microbiome-targeted therapies become standard AD treatment.

Future Perspectives

Advances in microbiome research have opened new opportunities for personalized medicine. Identifying microbial biomarkers may enable early diagnosis of neurological diseases, while targeted interventions precision probiotics, engineered microbes, dietary therapies, and microbiome-derived metabolites could offer novel treatment approaches [11]. Future research should focus on clarifying the molecular mechanisms underlying microbiome–brain communication and on developing robust clinical trial frameworks to translate these discoveries into effective, evidence-based therapies for patients with neurological and psychiatric conditions.

Conclusions

The microbiome–gut–brain axis represents one of the most significant advances in modern biomedical science, highlighting the intimate relationship between intestinal microbes and brain function. Communication occurs through neural, endocrine, immune, and metabolic pathways, allowing each system to influence the other throughout life. A balanced gut microbiome is essential for immune regulation, neurodevelopment, and neurological health; dysbiosis contributes to inflammation and the development of several neurological and psychiatric conditions, including Alzheimer's disease. Although many mechanistic pathways remain to be fully elucidated, continued research into the microbiome–gut brain axis offers exciting prospects for early diagnosis, disease prevention, and innovative microbiome-based therapies aimed at improving both gastrointestinal and neurological health outcomes.

References

1. M. Carabotti, A. Scirocco, M. A. Maselli, and C. Severi, "The gut brain axis: interactions between enteric microbiota, central and enteric nervous systems," Ann. Gastroenterol., vol. 28, no. 2, pp. 203–209, 2015.
2. J. F. Cryan et al., "The microbiota-gut-brain axis," Physiol. Rev., vol. 99, no. 4, pp. 1877–2013, 2019, doi: 10.1152/physrev.00018.2018.
3. https://www.sciencedirect.com/science/article/pii/S0959438825000893
4. A. B. Shreiner, J. Y. Kao, and V. B. Young, "The gut microbiome in health and in disease," Curr. Opin. Gastroenterol., vol. 31, no. 1, pp. 69–75, 2015.
5. Y. E. Borre et al., "Microbiota and neurodevelopmental windows: implications for brain disorders," Trends Mol. Med., vol. 20, no. 9, pp. 509–518, 2014.
6. E. Y. Hsiao et al., "Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders," Cell, vol. 155, no. 7, pp. 1451–1463, 2013.
7. E. A. Mayer, "Gut feelings: the emerging biology of gut–brain communication," Nat. Rev. Neurosci., vol. 12, no. 8, pp. 453–466, 2011.
8. P. Strandwitz, "Neurotransmitter modulation by the gut microbiota," Brain Res., vol. 1693, pp. 128–133, 2018.
9. N. Sudo et al., "Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice," J. Physiol., vol. 558, no. 1, pp. 263–275, 2004.
10. J. A. Foster and K.-A. McVey Neufeld, "Gut–brain axis: how the microbiome influences anxiety and depression," Trends Neurosci., vol. 36, no. 5, pp. 305–312, 2013.
11. T. G. Dinan, C. Stanton, and J. F. Cryan, "Psychobiotics: a novel class of psychotropic," Biol. Psychiatry, vol. 74, no. 10, pp. 720 726, 2013.

12. Alzheimer's Association, "2022 Alzheimer's disease facts and figures," Alzheimers Dement., vol. 18, no. 4, pp. 700–789, 2022.
13. T. Harach et al., "Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota," Sci. Rep., vol. 7, p. 41802, 2017.
14. T. R. Sampson and S. K. Mazmanian, "Control of brain development, function, and behavior by the microbiome," Cell Host Microbe, vol. 17, no. 5, pp. 565–576, 2015.
15. M. M. Wang et al., "Phytosterols modify gut microbiota, lipid metabolism and neuroinflammation in Alzheimer's disease models," Nutr. Neurosci., 10.1080/1028415X.2023.2284624. 2023, doi: